Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Adverum Biotechnologies, Inc is a biotechnology business based in the US. Adverum Biotechnologies shares (ADVM) are listed on the NASDAQ and all prices are listed in US Dollars. Adverum Biotechnologies employs 114 staff and has a trailing 12-month revenue of around USD$250,000.
Since the stock market crash in March caused by coronavirus, Adverum Biotechnologies's share price has had significant negative movement.
Its last market close was USD$11.56, which is 22.13% down on its pre-crash value of USD$14.845 and 57.07% up on the lowest point reached during the March crash when the shares fell as low as USD$7.36.
If you had bought USD$1,000 worth of Adverum Biotechnologies shares at the start of February 2020, those shares would have been worth USD$1,019.63 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,135.54.
|Latest market close||USD$11.56|
|52-week range||USD$6.58 - USD$26.98|
|50-day moving average||USD$11.5194|
|200-day moving average||USD$15.9591|
|Wall St. target price||USD$27.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.046|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||-8.83%|
|1 month (2020-10-26)||-2.69%|
|3 months (2020-08-26)||-6.09%|
|6 months (2020-05-26)||-43.44%|
|1 year (2019-11-26)||7.34%|
|2 years (2018-11-26)||214.13%|
|3 years (2017-11-24)||279.02%|
|5 years (2015-11-25)||16.18%|
|Gross profit TTM||USD$-40,169,000|
|Return on assets TTM||-20.86%|
|Return on equity TTM||-37.87%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 12.4 million Adverum Biotechnologies shares held short by investors – that's known as Adverum Biotechnologies's "short interest". This figure is 17.7% up from 10.5 million last month.
There are a few different ways that this level of interest in shorting Adverum Biotechnologies shares can be evaluated.
Adverum Biotechnologies's "short interest ratio" (SIR) is the quantity of Adverum Biotechnologies shares currently shorted divided by the average quantity of Adverum Biotechnologies shares traded daily (recently around 1.4 million). Adverum Biotechnologies's SIR currently stands at 9.09. In other words for every 100,000 Adverum Biotechnologies shares traded daily on the market, roughly 9090 shares are currently held short.
However Adverum Biotechnologies's short interest can also be evaluated against the total number of Adverum Biotechnologies shares, or, against the total number of tradable Adverum Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adverum Biotechnologies's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Adverum Biotechnologies shares in existence, roughly 130 shares are currently held short) or 0.1383% of the tradable shares (for every 100,000 tradable Adverum Biotechnologies shares, roughly 138 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Adverum Biotechnologies.
Find out more about how you can short Adverum Biotechnologies stock.
We're not expecting Adverum Biotechnologies to pay a dividend over the next 12 months.
Over the last 12 months, Adverum Biotechnologies's shares have ranged in value from as little as $6.58 up to $26.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adverum Biotechnologies's is 1.6839. This would suggest that Adverum Biotechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Redwood City, California.
Everything we know about the WorldRemit IPO, plus information on how to buy in.
Everything we know about the Jowell Global IPO, plus information on how to buy in.
Steps to owning and managing AIRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing ACER, with 24-hour and historical pricing before you buy.
Steps to owning and managing WST, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRNA, with 24-hour and historical pricing before you buy.
Steps to owning and managing OLED, with 24-hour and historical pricing before you buy.
Steps to owning and managing RARE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.